It has been known for several years that both GLP-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase endogenous GLP-1, protect cardiomyocytes from acute ischaemic damage and promote functional recovery after experimental myocardial infarction (MI) [15]. Here, GCG is linked to myocardial infarction.